Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats

Current Eye Research

Volumn 36, Issue 10, 2011, Pages 964-970

  Tokushige, Hideki ^a   Waki, Mitsunori ^a   Takayama, Yoshiko ^a   Tanihara, Hidenobu ^b  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Axonal regeneration; Glaucoma; Ocular blood flow; Retinal ganglion cells; ROCK; Y 39983

Indexed keywords

RHO KINASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; Y 39983;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; CELL CULTURE MONITORING; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL RABBIT; EYE BLOOD FLOW; IN VIVO STUDY; MALE; NERVE FIBER REGENERATION; NEURITE; NONHUMAN; OPTIC NERVE; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL;

ADMINISTRATION, TOPICAL; ANIMALS; ANIMALS, NEWBORN; AXONS; AXOTOMY; BLOOD FLOW VELOCITY; DOSE-RESPONSE RELATIONSHIP, DRUG; INTRAVITREAL INJECTIONS; LASER-DOPPLER FLOWMETRY; MALE; MICROSCOPY, PHASE-CONTRAST; NERVE REGENERATION; OPTIC DISK; PERIPHERAL NERVES; PYRIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REGIONAL BLOOD FLOW; RETINAL GANGLION CELLS; RHO-ASSOCIATED KINASES;

EID: 80053320552     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.599106     Document Type: Article

References (41)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-1720. (Pubitemid 38670330)
2. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994;39:23-42. (Pubitemid 24243493)
3. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol 1994;38 Suppl:S3-S6. (Pubitemid 124017796)
4. Geijssen HC. Studies on Normal Pressure Glaucoma. New York:Kugler;1991:195-213.
5. Araie M, Sekine M, Suzuki Y, Koseki N. Factors contributing to the progression of visual field damage in eyes with normal-tension glaucoma. Ophthalmology 1994;101:1440-1444. (Pubitemid 24319293)
6. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem 1996;120:215-228. (Pubitemid 26335910)
7. Narumiya S, Ishizaki T, Watanabe N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett 1997;410: 68-72. (Pubitemid 27283386)
8. Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A. Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol 1990;111:1001-1007.
9. Takaishi K, Sasaki T, Kato M et al. Involvement of Rho p21 small GTP-binding protein and its regulator in the HGFinduced cell motility. Oncogene 1994;9:273-279. (Pubitemid 24020959)
10. Kishi K, Sasaki T, Kuroda S, Itoh T, Takai Y. Regulation of cytoplasmic division of Xenopus embryo by Rho p21 and its inhibitory GDP/GTP exchange protein (Rho GDI).J Cell Biol 1993;120:1187-1195.
11. Hirata K, Kikuchi A, Sasaki T et al. Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem 1992;267:8719-8722.
12. Gong MC, Iizuka K, Nixon G et al. Role of guanine nucleotide- binding proteins-ras-family or trimeric proteins or both-in Ca2+ sensitization of smooth muscle. Proc Natl Acad Sci USA 1996;93:1340-1345.
13. Ishizaki T, Maekawa M, Fujisawa K et al. The small GTPbinding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996;15:1885-1893. (Pubitemid 26119224)
14. Kaufman PL. Pressure-dependent outflow. In: Hart WM, eds. Alder's Physiology of the Eye: Clinical Application, 9th ed. St. Louis:Mosby;1992:307- 335.
15. Epstein DL, Rohen JW. Morphology of the trabecular meshwork and inner-wall endothelium after cationized ferritin perfusion in the monkey eye. Invest Ophthalmol Vis Sci 1991;32:160-171.
16. Tian B, Geiger B, Epstein DL, Kaufman PL. Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci 2000;41:619-623. (Pubitemid 30158867)
17. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994. (Pubitemid 27485693)
18. Honjo M, Tanihara H, Inatani M et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;42:137-144. (Pubitemid 32059420)
19. Waki M, Yoshida Y, Oka T, Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-474. (Pubitemid 34253206)
20. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001;42: 1029-1037. (Pubitemid 32289800)
21. Tokushige H, Inatani M, Nemoto S et al. Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007;48:3216-3222. (Pubitemid 351261166)
22. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008;126:309-315. (Pubitemid 351398453)
23. Hirose M, Ishizaki T, Watanabe N et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol 1998;141:1625-1636. (Pubitemid 28309176)
24. Tamaki Y, Kawamoto E, Araie M, Eguchi S, Fujii H. An application of laser speckle phenomenon for noninvasive twodimensional evaluation of microcirculation in ocular fundus-a preliminary report. Jpn J Ophthalmol 1993;37:178-186. (Pubitemid 23230300)
25. Tamaki Y, Araie M, Kawamoto E, Eguchi S, Fujii H. Non-contact, two-dimensional measurement of tissue circulation in choroid and optic nerve head using laser speckle phenomenon. Exp Eye Res 1995;60:373-383.
26. Barres BA, Silverstein BE, Corey DP, Chun LL. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1988;1:791-803.
27. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998;39:972-981. (Pubitemid 28196682)
28. Nakajima E, Nakajima T, Minagawa Y, Shearer TR, Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005;94:701-708. (Pubitemid 40577304)
29. Quan MZ, Kosaka J, Watanabe M, Wakabayashi T, Fukuda Y. Survival of axotomized retinal ganglion cells in peripheral nerve-grafted ferrets. Invest Ophthalmol Vis Sci 1999;40:2360-2366. (Pubitemid 29418392)
30. Mizuno K, Koide T, Saito N et al. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 2002;43:3243-3250.
31. Mizuno K, Koide T, Shimada S, Mori J, Sawanobori K, Araie M. Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina. Invest Ophthalmol Vis Sci 2009;50:2839-2847.
32. Takayama J, Tomidokoro A, Tamaki Y, Araie M. Time course of changes in optic nerve head circulation after acute reduction in intraocular pressure. Invest Ophthalmol Vis Sci 2005;46:1409-1419. (Pubitemid 41685883)
33. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001;85:1252-1259. (Pubitemid 32929554)
34. Osborne NN, Ugarte M, Chao M et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999;43 Suppl 1:S102-S128. (Pubitemid 29328586)
35. Sugiyama T, Shibata M, Kajiura S et al. Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci 2011;52:64-69.
36. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007;21:167-177. (Pubitemid 46827850)
37. Yamashita T, Tohyama M. The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat Neurosci 2003;6:461-467. (Pubitemid 36514693)
38. Sandvig A, Berry M, Barrett LB, Butt A, Logan A. Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. Glia 2004;46:225-251. (Pubitemid 38679204)
39. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-398. (Pubitemid 40704122)
40. Tura A, Schuettauf F, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S. Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci 2009;50:452-461.
41. Sagawa H, Terasaki H, Nakamura M et al. A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp Neurol 2007;205:230-240. (Pubitemid 46617509)